- EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets a tumour-specific N-glycosylated epitope on both CEACAM5 and CEACAM6. 

- The Fast Track Designation highlights the potential of EBC-129 to address critical unmet needs in pancreatic ductal adenocarcinoma (PDAC).

- Updated clinical data from the ongoing Phase 1 study of EBC-129 will be presented at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Talin is a protein that plays an important role in the immune system by activating integrins, receptors that help cells attach to one another. Now a new study by Fox Chase Cancer Center researchers shows how talin has distinct binding modes for two types of integrins that are important in blood cells. It also highlights how switching modes can enhance the integrins, potentially making them stronger.

A new study, led by experts at the University of Nottingham, has found that young people suffering from certain types of cancer, such as bone tumours, are experiencing lengthy times to diagnosis.

The Childhood Cancer Diagnosis Study, which is published in the Lancet Regional Health - Europe, was funded by the National Institute for Health and Care Research (NIHR).

Childhood cancer has been declared a global disease burden, with early diagnosis a priority. The aim of this study was to help researchers understand the journey that children and young people experience from the start of their symptoms until they receive their cancer diagnosis.

To do this, the team of researchers, led by Dr Shaarna Shanmugavadivel, Professor Shalini Ojha and Professor David Walker from the School of Medicine at the University of Nottingham, collected the data of 1,957 children and young people (aged 0-18 years) diagnosed with cancer between September 2020 and March 2023.

University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Clinical Oncology Annual Meeting May 30 to June 3 in Chicago.